Lewy bodies (LBs) are α-synuclein (α-syn)-rich intracellular inclusions that are an important pathological hallmark of Parkinson disease and several other neurodegenerative diseases. Increasing evidence suggests that the aggregation of α-syn has a central role in LB formation and is one of the key processes that drive neurodegeneration and pathology progression in Parkinson disease. However, little is known about the mechanisms underlying the formation of LBs, their biochemical composition and ultrastructural properties, how they evolve and spread with disease progression, and their role in neurodegeneration. In this Review, we discuss current knowledge of α-syn pathology, including the biochemical, structural and morphological features of LBs observed in different brain regions. We also review the most used cellular and animal models of α-syn aggregation and pathology spreading in relation to the extent to which they reproduce key features of authentic LBs. Finally, we provide important insights into molecular and cellular determinants of LB formation and spreading, and highlight the critical need for more detailed and systematic characterization of α-syn pathology, at both the biochemical and structural levels. This would advance our understanding of Parkinson disease and other neurodegenerative diseases and allow the development of more-reliable disease models and novel effective therapeutic strategies.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Journal of Neurology Open Access 10 November 2022
Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons
Scientific Reports Open Access 13 October 2022
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
Molecular Neurodegeneration Open Access 24 September 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24 (2013).
Klein, C. & Westenberger, A. Genetics of Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2, a008888 (2012).
Bartels, T., Kim, N. C., Luth, E. S. & Selkoe, D. J. N-alpha-acetylation of α-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLOS ONE 9, e103727 (2014).
Binolfi, A. et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J. Am. Chem. Soc. 128, 9893–9901 (2006).
Spillantini, M. G. et al. α-Synuclein in Lewy bodies. Nature 388, 839–840 (1997). This is the first study that reports the presence of α-syn in LBs of post-mortem brain tissues of patients with PD and dementia with LBs.
Fujiwara, H. et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164 (2002). This is the first study that demonstrated, using mass spectrometry and phospho-specific antibodies, that α-syn in LBs is extensively phosphorylated at S129, thus paving the way for the use of pS129 α-syn as a key marker of LBs and α-syn pathology formation.
Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–29752 (2006). This study applies unbiased biochemical and mass spectrometry-based approaches to map α-syn PTMs in LBs from patients with dementia with LBs and demonstrates that LBs were enriched with multiple modified forms of α-syn, with phosphorylation at S129 being the most dominant modification.
Hasegawa, M. et al. Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. J. Biol. Chem. 277, 49071–49076 (2002).
Baba, M. et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884 (1998). This work uses antibodies raised against purified LBs to provide direct biochemical, immunohistochemical and immunoelectron microscopic evidence for the presence of aggregated and insoluble α-syn (full-length and truncated species) in LBs from patients with PD and dementia with LBs.
Crowther, R. A., Jakes, R., Spillantini, M. G. & Goedert, M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 436, 309–312 (1998).
Giasson, B. I. et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290, 985–989 (2000).
Li, W. et al. Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson’s disease-linked mutations. Proc. Natl Acad. Sci. USA 102, 2162–2167 (2005).
Moors, T. E. et al. Detailed structural orchestration of Lewy pathology in Parkinson’s disease as revealed by 3D multicolor STED microscopy. bioRxiv https://doi.org/10.1101/470476 (2018). This article examines the distribution of α-syn species and neurofilaments in nigral LBs and demonstrates concentric structural organization of LBs with truncated α-syn species dominating the core region, which is surrounded by layers of phosphorylated α-syn species and neurofilaments.
Duda, J. E. et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 157, 1439–1445 (2000).
Öhrfelt, A. et al. Identification of novel α-synuclein isoforms in human brain tissue by using an online NanoLC-ESI-FTICR-MS method. Neurochem. Res. 36, 2029–2042 (2011).
Kellie, J. F. et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson’s disease brain tissue by intact protein mass spectrometry. Sci. Rep. 4, 5797 (2014).
Jensen, P. H. et al. Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds α-synuclein filaments. J. Biol. Chem. 275, 21500–21507 (2000).
Ikenaka, K., Suzuki, M., Mochizuki, H. & Nagai, Y. Lipids as trans-acting effectors for α-synuclein in the pathogenesis of Parkinson’s disease. Front. Neurosci. 13, 693 (2019).
Shahmoradian, S. H. et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099–1109 (2019). In this study, the authors use advanced EM techniques to show that nigral LBs are composed of a complex and crowded mixture of vesicular structures, dysmorphic organelles, lipids and non-fibrillar α-syn species. Filaments of undefined composition are detected in some LB inclusions.
Mahul-Mellier, A. L. et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl Acad. Sci. USA 117, 4971–4982 (2020). This study describes a neuronal seeding-based model that reproduces several key events leading to the formation of LBs, including seeding, fibrillization and formation of inclusions that recapitulate many of the key biochemical, morphological and organizational features of bona fide LBs.
Iwatsubo, T. et al. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148, 1517–1529 (1996).
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473 (1998). This study shows that α-syn filaments can be isolated from LBs and suggests that α-syn forms the major filamentous component of LBs seen in previous EM studies of LBs.
Paleologou, K. E. et al. Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 1093–1101 (2009).
Roberts, R. F., Wade-Martins, R. & Alegre-Abarrategui, J. Direct visualization of α-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain. Brain 138, 1642–1657 (2015).
Sekiya, H. et al. Wide distribution of α-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol. 137, 455–466 (2019).
Forno, L. S. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J. Am. Geriatr. Soc. 17, 557–575 (1969).
Forno, L. S. & Norville, R. L. Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol. 34, 183–197 (1976). This is one of the early studies that demonstrates the compositional and ultrastructural diversity of LBs and reveals that some LBs are not only composed of filamentous structures but are also enriched in vesicular structures, mitochondria, multivesicular bodies and other organelles.
Langston, J. W. & Forno, L. S. The hypothalamus in Parkinson disease. Ann. Neurol. 3, 129–133 (1978).
Gibb, W. R. G., Scott, T. & Lees, A. J. Neuronal inclusions of Parkinson’s disease. Mov. Disord. 6, 2–11 (1991).
Kuusisto, E., Parkkinen, L. & Alafuzoff, I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 1241–1253 (2003). This study presents one of the most extensive profilings of the diversity of nigral pale bodies and LBs and explores the relationship between these two types of inclusions using immunohistochemical detection of α-syn, ubiquitin and p62.
Lewy, F. H. Paralysis agitans. I. Pathologische Anatomie.in Handbuch der Neurologie (ed. Lewandowsky, M)(1912).
Duvoisin, R. C. A brief history of parkinsonism. Neurol. Clin. 10, 301–316 (1992).
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211 (2003).
Hawkes, C. H., Del Tredici, K. & Braak, H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33, 599–614 (2007).
Rey, N. L., Wesson, D. W. & Brundin, P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol. Dis. 109, 226–248 (2018).
Atik, A., Stewart, T. & Zhang, J. Alpha-synuclein as a biomarker for Parkinson’s Disease. Brain Pathol. 26, 410–418 (2016).
Olanow, C. W., Stocchi, F., and Lang, A. Parkinson’s Disease: Non-motor and Non-dopaminergic Features (John Wiley & Sons, 2011).
Beyer, K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 112, 237–251 (2006).
Narhi, L. et al. Both familial Parkinson’s disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274, 9843–9846 (1999).
Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276, 2045–2047 (1997).
Greenbaum, E. A. et al. The E46K mutation in α-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800–7807 (2005).
Kosaka, K. Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol. 42, 127–134 (1978).
Wakabayashi, K. et al. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 96, 445–452 (1998). This study uses antibodies to full-length α-syn or the 42–62 domain of α-syn to demonstrate the presence of α-syn in degenerating neurites and intracytoplasmic accumulations (LBs, glial cytoplasmic inclusions, neuronal cytoplasmic inclusions and neuronal nuclear inclusions), which represent common pathological features of LB disease and multiple system atrophy.
Beyer, K. & Ariza, A. α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol. Neurobiol. 47, 509–524 (2013).
Huang, Y. & Halliday, G. Can we clinically diagnose dementia with Lewy bodies yet? Transl. Neurodegener. 2, 4 (2013).
Irwin, D. J., Lee, V. M. & Trojanowski, J. Q. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-beta pathologies. Nat. Rev. Neurosci. 14, 626–636 (2013).
Fares, M. B. et al. The novel Parkinson’s disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet 23, 4491–4509 (2014).
Li, B. et al. Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel. Nat. Commun. 9, 3609 (2018).
Araki, K. et al. Parkinson’s disease is a type of amyloidosis featuring accumulation of amyloid fibrils of α-synuclein. Proc. Natl Acad. Sci. USA 116, 17963–17969 (2019). Using microbeam X-ray diffraction, this study confirms that α-syn-positive LBs in the brains of patients contain fibrils that possess the cross-β structure characteristics for amyloid fibrils.
Lowe, J. et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson’s disease, Pick’s disease, and Alzheimer’s disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J. Pathol. 155, 9–15 (1988).
Kuzuhara, S., Mori, H., Izumiyama, N., Yoshimura, M. & Ihara, Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol. 75, 345–353 (1988). This study shows that all LBs from brainstem and cortical brain regions are recognized by antibodies to ubiquitin and demonstrates that peripherally located filaments in LBs are ubiquitinated, thus paving the way for the use of ubiquitin as a marker of LBs.
Ghosh, D. et al. The Parkinson’s disease-associated H50Q mutation accelerates alpha-synuclein aggregation in vitro. Biochemistry 52, 6925–6927 (2013).
Ishii, T., Haga, S. & Tokutake, S. Presence of neurofilament protein in Alzheimer’s neurofibrillary tangles (ANT). An immunofluorescent study. Acta Neuropathol. 48, 105–112 (1979).
Dahl, D., Selkoe, D. J., Pero, R. T. & Bignami, A. Immunostaining of neurofibrillary tangles in Alzheimer’s senile dementia with a neurofilament antiserum. J. Neurosci. 2, 113–119 (1982).
Rutherford, N. J., Moore, B. D., Golde, T. E. & Giasson, B. I. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein. J. Neurochem. 131, 859–867 (2014).
Kumar, S. et al. Role of sporadic parkinson disease associated mutations A18T and A29S in enhanced α-synuclein fibrillation and cytotoxicity. ACS Chem. Neurosci. 9, 230–240 (2018).
Goldman, J. E., Yen, S. H., Chiu, F. C. & Peress, N. S. Lewy bodies of Parkinson’s disease contain neurofilament antigens. Science 221, 1082–1084 (1983).
Duffy, P. E. & Tennyson, V. M. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson’s disease. J. Neuropathol. Exp. Neurol. 24, 398–414 (1965). This study presents the first ultrastructural characterization of LBs from the substantia nigra and locus coeruleus, revealing their composition and the presence of radiating filamentous structures from a dense central core, and lipofuscin positivity suggesting the presence of neuromelanin granules and lipid–protein complexes.
Forno, L. S. Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55, 259–272 (1996).
Ikeda, K., Hori, A. & Bode, G. Progressive dementia with “diffuse Lewy-type inclusions” in cerebral cortex. A case report. Arch. Psychiatr. Nervenkr 228, 243–248 (1980).
Yagishita, S., Itoh, Y., Amano, N. & Nakano, T. Atypical senile dementia with widespread Lewy type inclusion in the cerebral cortex. Acta Neuropathol. 49, 187–191 (1980).
Tomonaga, M. Neurofibrillary tangles and Lewy bodies in the locus ceruleus neurons of the aged brain. Acta Neuropathol. 53, 165–168 (1981).
Watanabe, I., Vachal, E. & Tomita, T. Dense core vesicles around the Lewy body in incidental Parkinson’s disease: an electron microscopic study. Acta Neuropathol. 39, 173–175 (1977).
Uéda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282–11286 (1993).
Culvenor, J. G. et al. Non-Aβ component of Alzheimer’s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Aβ amyloid. Am. J. Pathol. 155, 1173–1181 (1999).
Kahle, P. J. et al. Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159, 2215–2225 (2001).
Kuusisto, E., Suuronen, T. & Salminen, A. Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells. Biochem. Biophys. Res. Commun. 280, 223–228 (2001).
Monzio Compagnoni, G. & Di Fonzo, A. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathol. Commun. 7, 113 (2019).
Irizarry, M. C. et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57, 334–337 (1998).
Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269 (2000).
Dustin, P. & Brion, J. P. [Pathology of the cytoskeleton]. Ann. Pathol. 8, 3–19 (1988).
Leverenz, J. B. et al. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol. 17, 139–145 (2007). This is one of the first studies that sought to define the proteome of LBs by performing a proteomics investigation on 2,500 cortical LBs isolated by laser capture microdissection.
Basso, M. et al. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics 4, 3943–3952 (2004).
Werner, C. J., Heyny-von Haussen, R., Mall, G. & Wolf, S. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci. 6, 8 (2008).
Kitsou, E. et al. Identification of proteins in human substantia nigra. Proteom. Clin. Appl. 2, 776–782 (2008).
Licker, V. et al. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson’s disease pathogenesis. Proteomics 14, 784–794 (2014).
van Dijk, K. D. et al. The proteome of the locus ceruleus in Parkinson’s disease: relevance to pathogenesis. Brain Pathol. 22, 485–498 (2012).
Bereczki, E. et al. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain 141, 582–595 (2018).
den Jager, W. A. Sphingomyelin in Lewy inclusion bodies in Parkinson’s disease. Arch. Neurol. 21, 615–619 (1969). This is the first report that describes the presence of phospholipids (for example, sphingomyelin) in LBs from the substantia nigra and locus coeruleus.
Issidorides, M. R., Mytilineou, C., Panayotacopoulou, M. T. & Yahr, M. D. Lewy bodies in parkinsonism share components with intraneuronal protein bodies of normal brains. J. Neural Transm. Park. Dis. Dement. Sect. 3, 49–61 (1991).
Gai, W. P. et al. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 166, 324–333 (2000). In this study, the authors investigate the distribution of α-syn, ubiquitin and lipids within LBs, and their findings reveal that LBs are rich in lipids and are heterogeneous in their composition and organization.
Araki, K. et al. Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson’s disease patients. Sci. Rep. 5, 17625 (2015).
Shahmoradian, S. H. et al. Lewy pathology in Parkinson’s disease consists of a crowded organellar membranous medley. bioRxiv https://doi.org/10.1101/137976 (2017).
Lashuel, H. A. Do Lewy bodies contain alpha-synuclein fibrils? and does it matter? A brief history and critical analysis of recent reports. Neurobiol. Dis. 141, 104876 (2020). This review provides a critical analysis of the findings and conclusions presented in the article by Shahmoradian et al. (2019), which argues that LBs contain non-fibrillar rather than fibrillar forms of α-syn.
Greffard, S. et al. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol. Aging 31, 99–103 (2010).
Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson’s disease. Science 302, 841 (2003). This is the first study demonstrating that SNCA gene triplication can also cause familial PD.
Chartier-Harlin, M.-C. et al. α-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364, 1167–1169 (2004).
Zarranz, J. J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173 (2004).
Kruger, R. et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat. Genet. 18, 106–108 (1998).
Appel-Cresswell, S. et al. α-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov. Disord. 28, 811–813 (2013).
Kiely, A. P. et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? Acta Neuropathol. 125, 753–769 (2013).
Lesage, S. et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459–471 (2013).
Khalaf, O. et al. The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity. J. Biol. Chem. 289, 21856–21876 (2014).
McLean, P. J., Kawamata, H. & Hyman, B. T. α-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104, 901–912 (2001).
Petrucelli, L. et al. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007–1019 (2002).
Tabrizi, S. J. et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9, 2683–2689 (2000).
Tofaris, G. K., Layfield, R. & Spillantini, M. G. α-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22–26 (2001).
Welander, H. et al. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro. Biochem. Biophys. Res. Commun. 412, 32–38 (2011).
Pranke, I. M. et al. α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J. Cell Biol. 194, 89–103 (2011).
Outeiro, T. F. & Lindquist, S. Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302, 1772–1775 (2003).
Gitler, A. D. et al. The Parkinson’s disease protein α-synuclein disrupts cellular Rab homeostasis. Proc. Natl Acad. Sci. USA 105, 145–150 (2008).
Soper, J. H., Kehm, V., Burd, C. G., Bankaitis, V. A. & Lee, V. M. Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis. J. Mol. Neurosci. 43, 391–405 (2011).
Roberti, M. J., Bertoncini, C. W., Klement, R., Jares-Erijman, E. A. & Jovin, T. M. Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged α-synuclein. Nat. Methods 4, 345–351 (2007).
Wakabayashi, K. et al. Synphilin-1 is present in Lewy bodies in Parkinson’s disease. Ann. Neurol. 47, 521–523 (2000).
Xie, Y. Y. et al. Interaction with synphilin-1 promotes inclusion formation of α-synuclein: mechanistic insights and pathological implication. FASEB J. 24, 196–205 (2010).
Engelender, S. et al. Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22, 110–114 (1999).
Tanaka, M. et al. Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625–4631 (2004).
Eyal, A. & Engelender, S. Synphilin isoforms and the search for a cellular model of Lewy body formation in Parkinson’s disease. Cell Cycle 5, 2082–2086 (2006).
Smith, W. W. et al. α-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544–5552 (2005). In this study, Smith et al. report that the co-expression of α-syn and synphilin 1 causes the formation of inclusion bodies that are positive for pS129 α-syn, ubiquitin and ThS and that these inclusions are composed of disorganized filaments.
Buttner, S. et al. Synphilin-1 enhances α-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent manner. PLoS ONE 5, e13700 (2010).
Lee, G. et al. Casein kinase II-mediated phosphorylation regulates α-synuclein/synphilin-1 interaction and inclusion body formation. J. Biol. Chem. 279, 6834–6839 (2004).
O’Farrell, C. et al. Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. Brain Res. Mol. Brain Res. 97, 94–102 (2001).
Fares, M. B. et al. Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson’s disease. Proc. Natl Acad. Sci. USA 113, E912–E921 (2016). This study demonstrates that the lack of human α-syn fibrillization in rodent neuronal models could be due to interactions between human α-syn and the endogenously expressed mouse α-syn homologue, and shows that transient expression of human WT α-syn in Snca-knockout neurons leads to the formation of spheroid fibrillar inclusions that are insoluble, ThS positive and immunoreactive for antibodies to ubiquitin and pS129 α-syn.
Proukakis, C. et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 80, 1062–1064 (2013).
Hoffman-Zacharska, D. et al. Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson’s disease. Parkinsonism Relat. Disord. 19, 1057–1060 (2013).
Pasanen, P. et al. Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson’s disease-type pathology. Neurobiol. Aging 35, 2180.e1–2180.e5 (2014).
Farrer, M. et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55, 174–179 (2004).
Ibáñez, P. et al. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364, 1169–1171 (2004).
Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318–331 (2011).
Chung, C. Y. et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342, 983–987 (2013).
Ryan, Scott D. et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell 155, 1351–1364 (2013).
Dettmer, U. et al. Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun. 6, 7314 (2015).
Kouroupi, G. et al. Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson’s disease. Proc. Natl Acad. Sci. USA 114, E3679–E3688 (2017).
Devine, M. J. et al. Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat. Commun. 2, 440 (2011).
Byers, B. et al. SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS ONE 6, e26159 (2011).
Flierl, A. et al. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an α-synuclein gene triplication. PLoS ONE 9, e112413 (2014).
Oliveira, L. M. et al. Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson’s patient-derived induced pluripotent stem cells. Cell Death Dis. 6, e1994 (2015).
Lin, L. et al. Molecular features underlying neurodegeneration identified through in vitro modeling of genetically diverse Parkinson’s disease patients. Cell Rep. 15, 2411–2426 (2016).
Deas, E. et al. α-Synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson’s disease. Antioxid. Redox Signal. 24, 376–391 (2016).
Zambon, F. et al. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson’s iPSC-derived dopamine neurons. Hum. Mol. Genet. 28, 2001–2013 (2019).
Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson’s disease. Nature 404, 394–398 (2000). In this report, A30P α-syn overexpression in Drosophila leads to the formation of LB-like inclusions that exhibit some of the features of the classical brainstem LBs, including a dense core with peripherally radiating filaments.
Mizuno, H., Fujikake, N., Wada, K. & Nagai, Y. α-Synuclein transgenic drosophila as a model of Parkinson’s disease and related synucleinopathies. Parkinsons Dis. 2011, 212706 (2010).
Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M. & Bonini, N. M. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 295, 865–868 (2002).
Takahashi, M. et al. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155–158 (2003).
Chen, L. & Feany, M. B. α-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657–663 (2005).
Chen, L. et al. Tyrosine and serine phosphorylation of α-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest. 119, 3257–3265 (2009).
Ordonez, D. G., Lee, M. K. & Feany, M. B. α-synuclein induces mitochondrial dysfunction through spectrin and the actin cytoskeleton. Neuron 97, 108–124.e6 (2018).
Kuwahara, T. et al. Familial Parkinson mutant α-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 281, 334–340 (2006).
Lakso, M. et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. J. Neurochem. 86, 165–172 (2003).
van Ham, T. J. et al. C. elegans model identifies genetic modifiers of α-synuclein inclusion formation during aging. PLoS Genet. 4, e1000027 (2008).
Beal, M. F. Experimental models of Parkinson’s disease. Nat. Rev. Neurosci. 2, 325–334 (2001).
Kahle, P. J. α-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 115, 87–95 (2008).
Kahle, P. J. et al. Subcellular localization of wild-type and Parkinson’s disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365–6373 (2000).
Rockenstein, E. et al. Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68, 568–578 (2002).
van der Putten, H. et al. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021–6029 (2000).
Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O. M. & Sudhof, T. C. α-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383–396 (2005).
Rothman, S. M. et al. Neuronal expression of familial Parkinson’s disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice. J. Parkinsons Dis. 3, 215–229 (2013).
Neumann, M. et al. Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 1429–1439 (2002).
Emmer, K. L., Waxman, E. A., Covy, J. P. & Giasson, B. I. E46K human α-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J. Biol. Chem. 286, 35104–35118 (2011). This study describes an α-syn transgenic mouse model (expressing E46K human α-syn) that develops motor impairments and age-dependent intracytoplasmic inclusions that recapitulate some of the biochemical, histological, and morphological features of human LBs, including the accumulation of detergent-insoluble and phosphorylated α-syn fibrils and the presence of trapped membranous organelles (for example, mitochondria).
Giasson, B. I. et al. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521–533 (2002). This is one of the first α-syn transgenic mouse models (overexpressing A53T human α-syn), which develops age-dependent α-syn inclusions in the spinal cord that comprise fibrillar α-syn (10–16 nm) and are reminiscent of human cortical LBs and LNs in synucleinopathies.
Nuber, S. et al. A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain 136, 412–432 (2013).
Cannon, J. R. et al. Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson’s disease features and enhances vulnerability to mitochondrial impairment. Exp. Neurol. 240, 44–56 (2013).
Kuo, Y. M. et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated α-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 19, 1633–1650 (2010).
Matsuoka, Y. et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535–539 (2001).
Richfield, E. K. et al. Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp. Neurol. 175, 35–48 (2002).
Rathke-Hartlieb, S. et al. Sensitivity to MPTP is not increased in Parkinson’s disease-associated mutant α-synuclein transgenic mice. J. Neurochem. 77, 1181–1184 (2001).
Thiruchelvam, M. J., Powers, J. M., Cory-Slechta, D. A. & Richfield, E. K. Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice. Eur. J. Neurosci. 19, 845–854 (2004).
Wakamatsu, M. et al. Accumulation of phosphorylated α-synuclein in dopaminergic neurons of transgenic mice that express human α-synuclein. J. Neurosci. Res. 85, 1819–1825 (2007).
Wakamatsu, M. et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobiol. Aging 29, 574–585 (2008).
Wegrzynowicz, M. et al. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model. Acta Neuropathol. 138, 575–595 (2019).
Klein, R. L., King, M. A., Hamby, M. E. & Meyer, E. M. Dopaminergic cell loss induced by human A30P α-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605–612 (2002).
Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780–2791 (2002).
Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N. & Aebischer, P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 99, 10813–10818 (2002). This study reports a lentiviral α-syn overexpression-based model of PD that exhibits selective loss of nigral dopaminergic neurons and the appearance of human α-syn non-fibrillar positive inclusions and neuritic pathology. Similar inclusions are formed by rat α-syn in the absence of neuronal loss.
Yamada, M., Iwatsubo, T., Mizuno, Y. & Mochizuki, H. Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson’s disease. J. Neurochem. 91, 451–461 (2004).
Decressac, M., Mattsson, B., Lundblad, M., Weikop, P. & Bjorklund, A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiol. Dis. 45, 939–953 (2012).
Azeredo da Silveira, S. et al. Phosphorylation does not prompt, nor prevent, the formation of α-synuclein toxic species in a rat model of Parkinson’s disease. Hum. Mol. Genet. 18, 872–887 (2009). This study demonstrates that AAV-mediated expression of S129A α-syn in rat SNc induces abundant expression of ThS-positive, proteinase K-resistant aggregates, which are electron dense with occasional filamentous structures.
Paleologou, K. E. et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30, 3184–3198 (2010).
Kirik, D. et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 100, 2884–2889 (2003).
Eslamboli, A. et al. Long-term consequences of human α-synuclein overexpression in the primate ventral midbrain. Brain 130, 799–815 (2007).
Oliveras-Salva, M. et al. rAAV2/7 vector-mediated overexpression of α-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol. Neurodegener. 8, 44 (2013).
Lauwers, E. et al. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13, 364–372 (2003).
Cao, S., Theodore, S. & Standaert, D. G. Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson’s disease. Mol. Neurodegener. 5, 42 (2010).
Lundblad, M., Decressac, M., Mattsson, B. & Bjorklund, A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc. Natl Acad. Sci. USA 109, 3213–3219 (2012).
St Martin, J. L. et al. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 100, 1449–1457 (2007).
McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol. 179, 38–46 (2003).
Rideout, H. J. & Stefanis, L. Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination. Mol. Cell Neurosci. 21, 223–238 (2002).
Rideout, H. J., Larsen, K. E., Sulzer, D. & Stefanis, L. Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78, 899–908 (2001).
McNaught, K. S. et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81, 301–306 (2002).
Rideout, H. J., Dietrich, P., Wang, Q., Dauer, W. T. & Stefanis, L. α-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. J. Biol. Chem. 279, 46915–46920 (2004).
Paxinou, E. et al. Induction of α-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053–8061 (2001).
Bedford, L. et al. Depletion of 26 S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 28, 8189–8198 (2008). This study reports that 26S proteasomal dysfunction in conditional knockout mice is sufficient to trigger neurodegeneration and fibrillar or granular inclusions that are positive for ubiquitin, ThS and p62, and contain mitochondria and/or membranous vesicles in their periphery.
Sherer, T. B. et al. An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J. Neurosci. 22, 7006–7015 (2002).
Ostrerova-Golts, N. et al. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048–6054 (2000).
Kakimura, J. et al. Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417, 59–67 (2001).
Lee, H. J., Shin, S. Y., Choi, C., Lee, Y. H. & Lee, S. J. Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277, 5411–5417 (2002).
Erskine, D. et al. Lewy body pathology is more prevalent in older individuals with mitochondrial disease than controls. Acta Neuropathol. 139, 219–221 (2020).
Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979–980 (1983).
Langston, J. W. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598–605 (1999).
Giraldez-Perez, R., Antolin-Vallespin, M., Munoz, M. & Sanchez-Capelo, A. Models of α-synuclein aggregation in Parkinson’s disease. Acta Neuropathol. Commun. 2, 176 (2014).
Fornai, F. et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl Acad. Sci. USA 102, 3413–3418 (2005). This study demonstrates that continuous low-dose administration of MPTP produces progressive behavioural changes, causes α-syn-dependent inhibition of the ubiquitin–proteasome system and results in the formation of inclusions immunoreactive for ubiquitin and α-syn.
Gibrat, C. et al. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions. J. Neurochem. 109, 1469–1482 (2009).
Meredith, G. E. et al. Lysosomal malfunction accompanies α-synuclein aggregation in a progressive mouse model of Parkinson’s disease. Brain Res. 956, 156–165 (2002).
Meredith, G. E., Totterdell, S., Potashkin, J. A. & Surmeier, D. J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14, S112–S115 (2008).
Shimoji, M., Zhang, L., Mandir, A. S., Dawson, V. L. & Dawson, T. M. Absence of inclusion body formation in the MPTP mouse model of Parkinson’s disease. Brain Res. Mol. Brain Res 134, 103–108 (2005).
Alvarez-Fischer, D. et al. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J. Neurochem. 107, 701–711 (2008).
Forno, L. S., DeLanney, L. E., Irwin, I. & Langston, J. W. Similarities and differences between MPTP-induced parkinsonsim and Parkinson’s disease. Neuropathologic considerations. Adv. Neurol. 60, 600–608 (1993). This study compares neuropathological features between the MPTP-treated squirrel monkey model of PD and human PD pathology and describes similarities in neurodegeneration of the selected population of neurons and different morphologies of inclusions.
Kowall, N. W. et al. MPTP induces α-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211–213 (2000).
McCormack, A. L. et al. Pathologic modifications of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J. Neuropathol. Exp. Neurol. 67, 793–802 (2008).
Halliday, G. et al. No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov. Disord. 24, 1519–1523 (2009). In this study, the authors demonstrate that MPTP administration in monkeys induces the accumulation of α-syn, but is not sufficient to trigger the formation of classical LBs.
Fong, C. S. et al. Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson’s disease. Clin. Chim. Acta 378, 136–141 (2007).
Liou, H. H. et al. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 48, 1583–1588 (1997).
Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3, 1301–1306 (2000). This study demonstrates that long-term inhibition of complex I by rotenone causes selective nigral dopaminergic cell loss, and PD-like behavioural (hypokinesia and rigidity) and neuropathological features, including the formation of α-syn and ubiquitin-positive inclusions with a dense core and radiating filaments, reminiscent of LBs.
Sherer, T. B., Kim, J. H., Betarbet, R. & Greenamyre, J. T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp. Neurol. 179, 9–16 (2003).
McNaught, K. S., Perl, D. P., Brownell, A. L. & Olanow, C. W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann. Neurol. 56, 149–162 (2004).
Vernon, A. C., Johansson, S. M. & Modo, M. M. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson’s disease. BMC Neurosci. 11, 1 (2010).
Bezard, E., Yue, Z., Kirik, D. & Spillantini, M. G. Animal models of Parkinson’s disease: limits and relevance to neuroprotection studies. Mov. Disord. 28, 61–70 (2013).
Wakabayashi, K., Tanji, K., Mori, F. & Takahashi, H. The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology 27, 494–506 (2007).
Katsuse, O., Iseki, E., Marui, W. & Kosaka, K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J. Neurol. Sci. 211, 29–35 (2003).
Kanazawa, T. et al. Three-layered structure shared between Lewy bodies and Lewy neurites-three-dimensional reconstruction of triple-labeled sections. Brain Pathol. 18, 415–422 (2008). In this study, the authors use three-dimensional confocal image reconstruction of serial tissue sections that were triply immunolabelled with antibodies to α-syn, ubiquitin and neurofilaments to reveal the internal three-layered structure of LBs and LNs, and provide evidence in support of the hypothesis that LNs and LBs are related and possibly formed by similar mechanisms.
Iwai, A. et al. The precursor protein of non-Aβ component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467–475 (1995).
Jakes, R., Spillantini, M. G. & Goedert, M. Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27–32 (1994).
Withers, G. S., George, J. M., Banker, G. A. & Clayton, D. F. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res 99, 87–94 (1997).
Maraganore, D. M. et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661–670 (2006).
Farrer, M. et al. α-Synuclein gene haplotypes are associated with Parkinson’s disease. Hum. Mol. Genet. 10, 1847–1851 (2001).
Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat. Genet. 41, 1303–1307 (2009).
Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 41, 1308–1312 (2009).
Ray, S. et al. α-Synuclein aggregation nucleates through liquid-liquid phase separation. Nat. Chem. 12, 705–716 (2020).
Hardenberg, M. C. et al. Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies. bioRxiv https://doi.org/10.1101/2020.06.08.140798 (2020).
Mayer, R. J. et al. Ubiquitin, lysosomes and neurodegenerative diseases. Biochem. Soc. Trans. 20, 645–648 (1992).
Koffie, R. M. et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012–4017 (2009).
Dickson, D. W., Uchikado, H., Fujishiro, H. & Tsuboi, Y. Evidence in favor of Braak staging of Parkinson’s disease. Mov. Disord. 25, S78–S82 (2010).
Jellinger, K. A. Alpha-synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution–a pilot study. Acta Neuropathol. 106, 191–201 (2003).
Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503 (2008). This study along the work by Kordower et al. (Nat. Med., 2008) provides the first evidence that PD pathology can propagate from host to graft cell, as evidenced by the presence of LBs and LNs in grafted neurons, thus paving the way for new experimental approaches and hypotheses on the mechanisms of α-syn pathology spreading in the brain.
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 14, 504–506 (2008).
Chu, Y. & Kordower, J. H. Lewy body pathology in fetal grafts. Ann. N. Y. Acad. Sci. 1184, 55–67 (2010).
Kordower, J. H., Chu, Y., Hauser, R. A., Olanow, C. W. & Freeman, T. B. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord. 23, 2303–2306 (2008).
Li, J. Y. et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson’s disease. Mov. Disord. 25, 1091–1096 (2010).
Volpicelli-Daley, L. A. et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57–71 (2011). This study demonstrates that exogenous addition of PFFs to primary hippocampal neurons leads to seeding and formation of filamentous structures that are positive for several markers of LBs, such as pS129 α-syn, ubiquitin and p62, and formation of insoluble α-syn aggregates, a phenotype that was accompanied by synaptic dysfunction and cell death.
Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135–2146 (2014).
Volpicelli-Daley, L. A. et al. Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol. Biol. Cell 25, 4010–4023 (2014).
Wu, Q. et al. α-Synuclein (αSyn) preformed fibrils induce endogenous αSyn aggregation, compromise synaptic activity and enhance synapse loss in cultured excitatory hippocampal neurons. J. Neurosci. 39, 5080–5094 (2019).
Luk, K. C. et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051–20056 (2009). This study demonstrates that exogenous addition of PFFs to cultured cells leads to seeding and formation of inclusions that recapitulate several key features of LBs, including being fibrillar, insoluble, hyperphosphorylated and ubiquitinated.
Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015 (2009).
Guo, J. L. et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103–117 (2013).
Nonaka, T., Watanabe, S. T., Iwatsubo, T. & Hasegawa, M. Seeded aggregation and toxicity of α-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem. 285, 34885–34898 (2010).
Tran, H. T. et al. α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. 7, 2054–2065 (2014).
Waxman, E. A. & Giasson, B. I. Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J. Neurosci. 31, 7604–7618 (2011).
Burtscher, J., Copin, J. C., Sandi, C. & Lashuel, H. A. Pronounced α-synuclein pathology in a seeding-based mouse model is not sufficient to induce mitochondrial respiration deficits in the striatum and amygdala. eNeuro https://doi.org/10.1523/ENEURO.0110-20.2020 (2020).
Luk, K. C. et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975–986 (2012).
Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953 (2012).
Mahul-Mellier, A.-L. et al. The making of a Lewy body: the role of α-synuclein post-fibrillization modifications in regulating the formation and the maturation of pathological inclusions. bioRxiv https://doi.org/10.1101/500058 (2018). This study establishes the critical role of postfibrillization C-terminal truncation in the processing of α-syn fibrils, α-syn seeding, fibrillization, and LB formation and maturation.
Mougenot, A. L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225–2228 (2012).
Watts, J. C. et al. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl Acad. Sci. USA 110, 19555–19560 (2013).
Schweighauser, M. et al. Formaldehyde-fixed brain tissue from spontaneously ill α-synuclein transgenic mice induces fatal α-synucleinopathy in transgenic hosts. Acta Neuropathol. 129, 157–159 (2015).
Sacino, A. N. et al. Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J. Neurosci. 34, 12368–12378 (2014).
Sacino, A. N. et al. Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein. Acta Neuropathol. Commun. 1, 38 (2013).
Masuda-Suzukake, M. et al. Pathological α-synuclein propagates through neural networks. Acta Neuropathol. Commun. 2, 88 (2014).
Masuda-Suzukake, M. et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128–1138 (2013).
Tarutani, A. et al. The effect of fragmented pathogenic α-synuclein seeds on prion-like propagation. J. Biol. Chem. 291, 18675–18688 (2016).
Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351–362 (2014).
Luk, K. C. et al. Molecular and biological compatibility with host α-synuclein influences fibril pathogenicity. Cell Rep. 16, 3373–3387 (2016).
Rey, N. L. et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J. Exp. Med. 213, 1759–1778 (2016).
Thakur, P. et al. Modeling Parkinson’s disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain. Proc. Natl Acad. Sci. USA 114, E8284–E8293 (2017).
Shimozawa, A. et al. Propagation of pathological α-synuclein in marmoset brain. Acta Neuropathol. Commun. 5, 12 (2017).
Chu, Y. et al. Intrastriatal α-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain 142, 3565–3579 (2019).
Bourdenx, M. et al. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Sci. Adv. 6, eaaz9165 (2020).
Pieri, L., Madiona, K. & Melki, R. Structural and functional properties of prefibrillar α-synuclein oligomers. Sci. Rep. 6, 24526 (2016).
Marques, O. & Outeiro, T. F. α-synuclein: from secretion to dysfunction and death. Cell Death Dis. 3, e350 (2012).
Agnati, L. F. et al. A new hypothesis of pathogenesis based on the divorce between mitochondria and their host cells: possible relevance for Alzheimer’s disease. Curr. Alzheimer Res. 7, 307–322 (2010).
Lee, H. J., Patel, S. & Lee, S. J. Intravesicular localization and exocytosis of α-synuclein and its aggregates. J. Neurosci. 25, 6016–6024 (2005).
Lee, H. J. et al. Dopamine promotes formation and secretion of non-fibrillar α-synuclein oligomers. Exp. Mol. Med. 43, 216–222 (2011).
Jang, A. et al. Non-classical exocytosis of α-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 113, 1263–1274 (2010).
Hasegawa, T. et al. The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein. PLoS ONE 6, e29460 (2011).
Liu, J. et al. Rab11a and HSP90 regulate recycling of extracellular α-synuclein. J. Neurosci. 29, 1480–1485 (2009).
Alvarez-Erviti, L. et al. Lysosomal dysfunction increases exosome-mediated α-synuclein release and transmission. Neurobiol. Dis. 42, 360–367 (2011).
Emmanouilidou, E. et al. Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838–6851 (2010).
Danzer, K. M. et al. Exosomal cell-to-cell transmission of α synuclein oligomers. Mol. Neurodegener. 7, 42 (2012).
Guo, J. L. & Lee, V. M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130–138 (2014).
Mahul-Mellier, A. L. et al. Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death. Cell Death Differ. 22, 2107–2122 (2015).
Volles, M. J. & Lansbury, P. T. Jr Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595–4602 (2002).
Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. & Lansbury, P. T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
Quist, A. et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl Acad. Sci. USA 102, 10427–10432 (2005).
Pountney, D. L., Voelcker, N. H. & Gai, W. P. Annular α-synuclein oligomers are potentially toxic agents in α-synucleinopathy. Hypothesis. Neurotox. Res. 7, 59–67 (2005).
Tsigelny, I. F. et al. Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 279, 1000–1013 (2012).
Ouberai, M. M. et al. α-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J. Biol. Chem. 288, 20883–20895 (2013).
Kayed, R. et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46363–46366 (2004).
Reynolds, N. P. et al. Mechanism of membrane interaction and disruption by α-synuclein. J. Am. Chem. Soc. 133, 19366–19375 (2011).
Hellstrand, E., Nowacka, A., Topgaard, D., Linse, S. & Sparr, E. Membrane lipid co-aggregation with α-synuclein fibrils. PLoS ONE 8, e77235 (2013).
Varkey, J. et al. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J. Biol. Chem. 285, 32486–32493 (2010).
Pandey, A. P., Haque, F., Rochet, J. C. & Hovis, J. S. α-Synuclein-induced tubule formation in lipid bilayers. J. Phys. Chem. B 115, 5886–5893 (2011).
Holmes, B. B. et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA 110, E3138–E3147 (2013).
Hansen, C. et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715–725 (2011).
Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular α-synuclein-a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92–98 (2014).
Weissmann, C., Enari, M., Klohn, P. C., Rossi, D. & Flechsig, E. Transmission of prions. Proc. Natl Acad. Sci. USA 99, 16378–16383 (2002).
Dujardin, S. et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat. Med. 26, 1256–1263 (2020).
Bauerlein, F. J. B. et al. In situ architecture and cellular interactions of PolyQ inclusions. Cell 171, 179–187.e10 (2017).
Mamais, A. et al. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson’s disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol. Dis. 58, 183–190 (2013).
Spillantini, M. G. et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205–208 (1998).
Halliday, G. et al. Milestones in Parkinson’s disease — clinical and pathologic features. Mov. Disord. 26, 1015–1021 (2011).
Lashuel, H. A. et al. α-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089–1102 (2002).
Dhillon, S. J.-K. et al. A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLoS ONE 12, e0184731 (2017).
Gründemann, J., Schlaudraff, F., Haeckel, O. & Liss, B. Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease. Nucleic Acids Res. 36, e38 (2008).
Glaab, E. & Schneider, R. Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson’s disease. Neurobiol. Aging 74, 1–13 (2015).
Hernandez, S. M., Tikhonova, E. B. & Karamyshev, A. L. Protein–protein interactions in α-synuclein biogenesis: new potential targets in Parkinson’s disease. Front. Aging Neurosci. 12, 72 (2020).
Wood, S. J. et al. α-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease. J. Biol. Chem. 274, 19509–19512 (1999).
Qin, Z., Hu, D., Han, S., Hong, D. P. & Fink, A. L. Role of different regions of α-synuclein in the assembly of fibrils. Biochemistry 46, 13322–13330 (2007).
Conway, K. A., Harper, J. D. & Lansbury, P. T. Jr Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39, 2552–2563 (2000).
Giasson, B. I., Uryu, K., Trojanowski, J. Q. & Lee, V. M. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619–7622 (1999).
Harper, J. D. & Lansbury, P. T. Jr Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385–407 (1997).
Bousset, L. et al. Structural and functional characterization of two α-synuclein strains. Nat. Commun. 4, 2575 (2013).
Peelaerts, W. et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340–344 (2015).
Gribaudo, S. et al. Propagation of α-synuclein strains within human reconstructed neuronal network. Stem Cell Rep. 12, 230–244 (2019).
Guerrero-Ferreira, R. et al. Two new polymorphic structures of α-synuclein solved by cryo-electron microscopy. bioRxiv https://doi.org/10.1101/654582 (2019).
Guerrero-Ferreira, R. et al. Cryo-EM structure of α-synuclein fibrils. eLife 7, e36402 (2018).
Boyer, D. R. et al. The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. Proc. Natl Acad. Sci. USA 117, 3592–3602 (2020).
Boyer, D. R. et al. Cryo-EM structures of α-synuclein fibrils with the H50Q hereditary mutation reveal new polymorphs. bioRxiv https://doi.org/10.1101/738450 (2019).
Schweighauser, M. et al. Structures of α-synuclein filaments from multiple system atrophy. bioRxiv https://doi.org/10.1101/2020.02.05.935619 (2020).
Strohäker, T. et al. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nat. Commun. 10, 5535 (2019).
Shahnawaz, M. et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578, 273–277 (2020).
The authors are grateful to A.-L. Mahul-Mellier, R. Hegde, S. Donzelli, S. Novello, I. Rostami and N. Riguet for their critical inputs regarding supplementary tables 2 and 3, and thank G. Limorenko, R. Hegde and S. Novello for help in revising galley proofs.
H.A.L. has received funding from industry to support research on neurodegenerative diseases, including from Merck Serono, UCB and Abbvie. These companies had no specific role in the in the conceptualization and preparation of and decision to publish this work. H.A.L is also the co-founder and Chief Scientific Officer of ND BioSciences SA, a company that develops diagnostics and treatments for neurodegenerative diseases based on platforms that reproduce the complexity and diversity of proteins implicated in neurodegenerative diseases and their pathologies. M.B.F. is a co-founder of ND BioSciences SA and Director of Research and Development in the company. S.J. declares no competing interests.
Peer review information
Nature Reviews Neuroscience thanks S. Gentleman, M. Hasegawa and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
A term commonly used to describe the localized accumulation of proteins in cells or tissues as determined by their immunoreactivity to specific antibodies or detection of fluorescent puncta when the protein of interest is fused to fluorescent proteins. Not all inclusions represent the accumulation of aggregated proteins, unless verified by other biophysical or biochemical techniques.
- Lewy bodies
(LBs). One of the key pathological hallmarks of Parkinson disease and other synucleinopathies. They comprise intracellular globular cytoplasmic inclusions that contain complex mixtures of proteins, lipids and membranous organelles, and are enriched in aggregated forms of α-synuclein, predominantly insoluble fibrillar species.
- Lewy neurites
(LNs). A pathological hallmark of Parkinson disease. These are dystrophic processes containing protein accumulations that share many of the biochemical and immunohistological properties of Lewy bodies, including the presence of phosphorylated filamentous α-synuclein aggregates, although their ultrastructural features and biochemical composition remain less well characterized.
A term that refers to the process underlying the spreading of pathological aggregates in the brain through the transfer of seeding-competent protein aggregates from one cell to another.
Soluble peptide or protein assemblies (dimers or multimers) that exhibit different sizes, secondary structures and shapes (for example, spherical, pore-like and curvilinear structures).
Insoluble filamentous structures (8–12 nm in diameter) that form as a result of the misfolding and self-assembly of a peptide or a protein (for example, α-synuclein) via formation of repeating β-sheet structures, also known as cross-β structure, which is responsible for their unique binding to specific dyes (for example, thioflavin T, thioflavin S, Amytracker and Congo red), and allows them to be distinguished from other β-sheet-rich proteins.
- Amorphous aggregates
Aberrant protein aggregates that do not exhibit a specific ordered organization or morphology, that is, they are non-fibrillar.
- Pale bodies
Usually referred to as precursors to Lewy bodies, pale bodies are proteinaceous accumulations enriched with aggregated α-synuclein but do not exhibit many of the morphological, organizational and biochemical properties of mature Lewy bodies.
Relatively stable aggregates that can be prepared in vitro (such as fragmented fibrils) or isolated from pathological inclusions (such as Lewy bodies or glial cytoplasmic inclusions), total brain homogenates or the cerebrospinal fluid of patients with Parkinson disease or other synucleinopathies. When added to solutions or cells that have monomeric α-syn subunits, seeds accelerate their conversion to fibrils (in vitro) or to fibrils and Lewy body-like structures in neurons.
About this article
Cite this article
Fares, M.B., Jagannath, S. & Lashuel, H.A. Reverse engineering Lewy bodies: how far have we come and how far can we go?. Nat Rev Neurosci 22, 111–131 (2021). https://doi.org/10.1038/s41583-020-00416-6
This article is cited by
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
Molecular Neurodegeneration (2022)
Nature Reviews Neuroscience (2022)
Nature Reviews Neuroscience (2022)
Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons
Scientific Reports (2022)
Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases
Molecular Neurobiology (2022)